

Financial Report

2024



SAKK in Figures



1 network

for Clinical Cancer Research with a global impact

20

research groups

conduct cross-center clinical cancer studies across all types of cancer and all disciplines throughout Switzerland

11

young oncologists

who joined the Young Oncology Academy 2024 to make contributions to oncology

67

active clinical trials

– thereof 27 actively recruiting



69 employees

—a dedicated team with 58.3 full-time positions—make an effort for better chances of recovery and improved quality of life for patients

38

scientific articles

published, 18 poster presentations and 23 oral presentations at major oncology congresses



8 awards

for cancer research projects, honored by SAKK and partners

792

patients

newly recruited into trials in 2024, trusted in our research and participated in our trials. Thank you!

12

SAKK projects

and four external research ideas were discussed with the Patient Advisory Board

Contents

Goals

Editorial by the President	4
----------------------------	---

Together

Editorial by the CFO	5
Our Donors	6
Promoting Dialog	7
Organization Chart	8

Financial Statements

Balance Sheet	9
Statement of Operations	10
Cash Flow Statement	11
Statement of Changes in Capital	12
Statement of Changes in Funds	13

Annex

Notes to the 2024 Annual Financial Statements	14
Auditor's Report	17
Publishing Details	19



Annual Portrait

The Financial Report is published as an addendum to the Annual Portrait. This reports on the events of 2024 and provides an insight into SAKK’s activities.

Making Meaningful Progress in the Fight Against Cancer

2024 has been marked by stable financial success, a strong commitment to our collaborations and our mission. Introducing a lean academic trial module was a major milestone in improving research efficiency.



SAKK is pleased to report that, for the third consecutive year, we have closed our financial year with a positive result, an important milestone in our ongoing financial recovery.

This success has only been possible thanks to the continued support of our main grant providers: the State Secretariat for Education, Research and Innovation (SERI), Swiss Cancer Research and the Rising Tide Foundation. We extend our heartfelt gratitude to these institutions. Equally important was the dedication of our Board members, particularly the financial commission, whose strategic oversight has been instrumental in achieving financial stability. We also acknowledge the special efforts of our new CEO and the entire staff at the Competence Center, whose outstanding commitment have significantly contributed to our financial performance.

The solid financial standing has allowed us to reinvest in critical clinical trial activities. In 2025, we plan to open 21 new studies, reinforcing our commitment to stay Switzerland's leading clinical cancer research institution. We also initiated discussions with the Swiss National Science Foundation (SNSF) and Swiss Cancer Research to explore ways to further

promote clinical cancer research. As a result, we are developing a new funding strategy together with Swiss Cancer Research to help both organizations create additional financial support.

Strengthening our relationships with key stakeholders has been another focus this year. We have made significant strides in establishing connections with health insurers to explore their contributions to clinical cancer research. Furthermore, we have engaged with the Swiss Conference of the Cantonal Health Directors to discuss potential cantonal support.

A major milestone in our efforts to improve research efficiency has been the initiation of a lean academic trial module. This innovative concept is designed to streamline processes, significantly reduce costs and increase transparency, thus providing financial and scientific advantages to researchers and patients alike. Over the next few months, we will be testing this modular approach.

Looking ahead, we are confident that our strengthened financial position, strategic partnerships and innovative research approaches will enable us to expand opportunities

within our network. Our ultimate goal remains clear: advancing clinical cancer research to benefit all cancer patients in Switzerland. With our collective efforts and the support of our stakeholders, we are well-positioned to make meaningful progress in the fight against cancer.

Prof. Dr. med. Miklos Pless

SAKK Board President

Committed to the Future

For the third year in a row, SAKK has achieved a positive balance. In addition to the stable operating result, our financial assets performed well. A large legacy donation further ensures financial stability and confirms our positive public perception.



For the third consecutive year, SAKK has achieved a positive financial balance, reinforcing the stability and sustainability of our organization. In addition to a stable operating result, our financial assets performed exceptionally well, reflecting prudent management and a well-diversified investment strategy.

A particularly noteworthy development in 2024 was the receipt of a significant legacy donation, which serves as a testament to the positive public perception of SAKK and the trust we have built over the years. This generous contribution, along with other financial inflows, ensures stable and secure funding for 2025 and beyond. With this strong financial foundation, we can expand our initiatives, invest in pioneering research, and further develop innovative treatment approaches that benefit cancer patients in Switzerland.

Beyond financial success, we have worked diligently to refine and optimize our internal processes, ensuring that our operations remain efficient and effective. One of the key advancements in this area has been the development of a new and comprehensive fundraising strategy. This strategy will help us to broaden our sources of income even further.

As a result, we are financially well-equipped for the future, always committed to our core mission of bringing progress to cancer care and providing cancer patients in Switzerland with innovative treatment options. Through our research projects, we continue to optimize therapies, enhancing both the effectiveness and accessibility of treatment options. This not only improves the chances of recovery for cancer patients but also contributes to extending life expectancy and enhancing the overall quality of life for those affected by this disease.

Stefan Demetz
CFO

Legacy donation ensures financial stability for SAKK.

Stefan Demetz, CFO

Our Donors

Public sector and third parties

Alfred und Anneliese Sutter-Stöttner Stiftung
All.Can Switzerland Association
Cancer League Switzerland (Krebsliga)
City of Zurich
Hedy Glor-Meyer Stiftung
Klinikum der Universität München
MediCongress GmbH
Norges teknisk-naturvitenskapelige universitet NTNU
PlayToKnow AG
SOHC Board of Trustees Swiss Oncology & Hematology
State Secretariat for Education, Research and Innovation
SERI
Swiss Cancer Research Foundation
Swiss Foundation for Clinical Cancer Research SSKK
Swiss Paediatric Oncology Group SPOG
Swiss Personalized Health Network (SPHN)
Unicancer – Federation of Cancer Centers
University of Basel
University of Bern
University of Zurich

Industry

AbbVie AG Switzerland
Accord Healthcare AG
Amgen Switzerland AG
Astellas Pharma AG Switzerland
Astellas Pharma Europe Ltd.
AstraZeneca AG
Bayer (Schweiz) AG, Zurich
Bayer Consumer Care AG
BeiGene Switzerland GmbH
Bilthoven Biologicals B.V.
Breastceuticals AG
Bristol-Myers Squibb SA
Daiichi Sankyo (Switzerland) AG

Eli Lilly (Suisse) SA
F. Hoffmann-La-Roche Ltd.
Fédération Francophone de Cancérologie Digestive FFCD
Gilead Sciences Switzerland Sàrl
GlaxoSmithKline AG
Helvepharm AG
IDEOGEN AG
Immunophotonics Inc.
Incyte Biosciences International Sàrl
InnoMedica Schweiz AG
Intensity Therapeutics, CT
IPSEN Pharma Schweiz GmbH
Janssen Pharmaceutica NV
Janssen-Cilag AG
Merck (Schweiz) AG
MSD Merck Sharp & Dohme AG
Myriad Genetics GmbH
Novartis Pharma Schweiz AG
Nurix Therapeutics Inc., CA
PEAK Medicals GmbH
Pfizer AG
Pharma Mar SA
Pierre Fabre Pharma AG
Release Therapeutics
Roche Pharma (Schweiz) AG
Sanofi-Aventis (Schweiz) AG
Servier (Suisse) S.A.
Stemline Therapeutics Switzerland GmbH
Takeda Pharma AG

International research groups

ABCSG Research Services GmbH
AGO Research GmbH
ETOP IBCSG Partners Foundation
European Organization for Research and Treatment of Cancer (AISBL/IVZW) EORTC

Exact Sciences International GmbH
GHSG Studienzentrale
HOVON Stichting
IRCCS – Istituto di Ricerche Farmacologiche Mario Negri
LYSARC, The Lymphoma Academic Research Organization
Novocure GmbH
St. Clara Forschung AG

Additional donations from our members

Cantonal Hospital Aarau AG
Cantonal Hospital Baden AG
Cantonal Hospital Fribourg HFR
Cantonal Hospital Graubünden
Cantonal Hospital St.Gallen
Cantonal Hospital Winterthur
Charité – University Medicine Berlin
Geneva University Hospitals HUG
Hôpital du Valais
Hug Oncology Department
Insel Gruppe AG
Istituto di Imaging Della Svizzera Italiana (IIMSI)
Landeskrankenhaus Feldkirch
Lausanne University Hospital (CHUV)
LUKS Spitalbetriebe AG
Oncology Institute of Southern Switzerland (IOSI)
Onkozentrum Zurich
Réseau Hospitalier Neuchâtelois (RHNe)
Solothurner Spitäler AG
Spital STS AG Thun
Spital Thurgau AG
Spitalzentrum Biel AG
University Hospital Basel
University Hospital Zurich
University Medical Center of J. Gutenberg University Mainz
University of Geneva

Promoting Dialog

SAKK advances the development of effective cancer treatments by collaborating and hosting initiatives such as training, events and symposia that open new perspectives for treatment.

At meetings held in parallel with the ESMO and ASCO congresses, participants explored innovative approaches in cancer research. Introductory courses in Lausanne and St. Gallen deepened participants' understanding of genetic counseling in oncology. At the semi-annual meeting in June, SAKK presented six awards in collaboration with other partners. The Patient Advisory Board's engagement in various events proved to be highly valuable. Notably, their participation in the inaugural Swiss Symposium on Patient and Public Participation/Engagement (PPIE) in healthcare was particularly significant.

At its semi-annual meeting held at the Lucerne Culture and Convention Centre, SAKK presented five awards and one research grant worth a total of CHF 1,160,000 to particularly promising studies relating to clinical cancer research.

- SAKK/AbbVie Digital Innovation Award
- SAKK/Astellas GU-Oncology Award
- SAKK/BMS HEM Pioneer Grant
- SAKK/Gilead Expanding Horizons in Oncology Award
- SAKK/Novartis Together for Patients Award
- SAKK Network Trial Award 2023–2024

January 13, 2024
GU Cancer Forum
Zurich

January 16, 2024
GU Cancer Forum
Lausanne

January 30, 2024
SAKK Training Course for CRCs and CTNs
Bern

February 22, 2024
Forum dei pazienti
Lugano

February 23–24, 2024
Introductory Course in Genetic Counseling in Oncology
St. Gallen

March 13, 2024
GU Cancer Forum
Lugano

May 17, 2024
Swiss Consensus Conference for functional and oncological follow-up after cystectomy and trimodal therapy
Lucerne

June 06–08, 2024
Chicago in the Mountains
Flüeli-Ranft

June 25–27, 2024
SAKK Semi-Annual Meeting
Lucerne

August 15, 2024
Post APCCC
Bern

August 22, 2024
Industry Pool Meeting
Bern

August 29, 2024
SAKK Training Course for CRCs and CTNs
Bern

September 06–07, 2024
Introductory Course in Genetic Counseling in Oncology
Lausanne


September 25, 2024
ESMO in the Alps
Lucerne

November 07–08, 2024
5th Swiss SAKK Translational Urogenital Cancer Network Meeting & Award
– SAKK / Astellas & AstraZeneca
GU Research Award
– SAKK / Novartis Prostate Cancer
Award
Bern

November 20–22, 2024
SOHC/SAKK Semi-Annual Meeting
Basel

Organization Chart

SAKK



Balance Sheet

As at December 31
in CHF

	Annex	2024	2023
Assets			
Cash and cash equivalents		9,954,588	9,825,861
Accounts receivable	1)	1,566,340	1,433,782
Other accounts receivable		386,099	68,973
Prepaid expenses and accrued income	2)	546,008	650,686
Total current assets		12,453,035	11,979,302
Financial assets	3)	24,582,684	20,801,398
Total fixed assets		24,582,684	20,801,398
Total assets		37,035,719	32,780,700

As at December 31
in CHF

	Annex	2024	2023
Liabilities			
Accounts payable	4)	1,738,802	2,069,126
Accrued liabilities and deferred income	5)	18,041,048	16,901,190
Total short-term liabilities		19,779,850	18,970,315
Other provisions		242,398	251,036
Total long-term liabilities		242,398	251,036
"Special purpose" fund		145,932	270,932
"Hubacher" fund		10,275,984	9,429,490
Total special purpose fund capital		10,421,916	9,700,422
Organizational capital			
Free capital as at January 1		3,858,927	3,768,544
Group result		2,732,628	90,383
Free capital as at December 31		6,591,555	3,858,927
Total organizational capital		6,591,555	3,858,927
Total liabilities		37,035,719	32,780,700

Statement of Operations

January 1 to December 31
in CHF

	Annex	2024	2023	
Operating income				
Research contributions SERI		5,664,390	5,805,172	
Research contributions KLS		–	–57,400	
Research contributions KFS		887,285	1,043,878	
Research contributions SSKK		55,000	128,500	
Research contributions, third parties		468,159	164,255	
Research contributions, Swiss health insurers		218,774	1,785,348	
Income from industry partnerships		6,134,777	4,309,408	
Income from foreign trial groups		144,756	565,484	
Income from Patient Advisory Board		14,706	54,097	
Donations, bequests, legacies		2,662,778	236,727	
Miscellaneous income		2,110,991	1,608,639	
Losses on receivables		–21,642	61,189	
Total operating income		18,339,975	15,705,297	100.0%
Operating costs				
Miscellaneous trial-related expenses		–1,727,768	–1,051,446	
Research contributions, sites		–3,438,147	–3,185,436	
Events, congresses and hospitality expenses		–1,291,698	–1,330,209	
Other operating expenses		–66,321	108,959	
Total operating expenses		–6,523,934	–5,458,132	–34.8%
Interim result 1		11,816,041	10,247,166	65.2%

January 1 to December 31
in CHF

	Annex	2024	2023	
Coordination expenses				
Personnel expenses	6)	–8,481,757	–8,683,797	
Other coordination expenses		–1,525,815	–1,439,013	
Advertising expenses		–233,694	–366,339	
Total coordination expenses		–10,241,267	–10,489,149	–55.8%
Interim result 2		1,574,775	–241,983	8.6%
Financial result				
Financial income		1,341,272	590,284	
Financial expenses		–183,419	–257,918	
Total financial result		1,157,853	332,366	6.3%
Interim result 3		2,732,628	90,383	14.9%
Out-of-period result				
Out-of-period income		–	–	
Out-of-period expenses		–	–	
Total out-of-period result		–	–	0.0%
Annual result		2,732,628	90,383	14.9%

Cash Flow Statement

January 1 to December 31
in CHF

	2024	2023
+/- Annual gain (+) / loss (-)	2,732,628	90,383
+/- Depreciation/value adjustments (+) and additions (-) to fixed assets / appreciation	-3,781,286	-5,031,550
+/- Recognition (+) and reversal (-) of provisions	-8,638	251,036
+/- Depreciation (+) and appreciation (-) of listed short-term assets	-	-
+/- Decrease (+) / increase (-) in short-term receivables	-449,684	196,361
+/- Decrease (+) / increase (-) in prepaid expenses	104,678	657,323
+/- Increase (+) / decrease (-) in short-term liabilities	-330,324	93,985
+/- Increase (+) / decrease (-) in deferred income	1,139,858	1,073,375
+/- Other cash flow-neutral expenses (+) and income (-)	721,494	641,040
= Cash flow from operating activities	128,726	-2,028,046
- Investments in financial assets	-	-
+ Divestment of financial assets	-	-
= Cash flow from investing activities	-	-
+/- Assumption (+) / repayment (-) of short- and long-term financial liabilities	-	-
+/- Capital increases (+) / repayments (-)	-	-
= Cash flow from financing activities	-	-
Increase or decrease in cash and cash equivalents	128,726	-2,028,046

January 1 to December 31
in CHF

	2024	2023
Change in cash and cash equivalents		
As at start of reporting year	9,825,861	11,853,908
As at end of reporting year	9,954,588	9,825,861
Increase (+) / decrease (-) in cash and cash equivalents	128,726	-2,028,046

Statement of Changes in Capital

In CHF	Free capital	Net profit (+) Net loss (-)	Value fluctuation reserve Securities	Total
2024				
Holding January 1, 2024	3,858,927	–	–	3,858,927
Change in reserves	–	–	–	–
Annual result	2,732,628	–	–	2,732,628
Holding December 31, 2024	6,591,555	–	–	6,591,555

In CHF	Free capital	Net profit (+) Net loss (-)	Value fluctuation reserve Securities	Total
2023				
Holding January 1, 2023	3,768,544	–	–	3,768,544
Change in reserves	–	–	–	–
Annual result	90,383	–	–	90,383
Holding December 31, 2023	3,858,927	–	–	3,858,927

Statement of Changes in Funds

In CHF	"Education Grant" fund ¹	"Special purpose" fund ²	"Hubacher" fund ³	Total
2024				
Holding				
January 1, 2024	–	270,932	9,429,490	9,700,422
Fund creation	–	–	–	–
Fund income	–	–	846,494	846,494
Fund costs	–	–	–	–
Fund use	–	–125,000	–	–125,000
Holding				
December 31, 2024	–	145,932	10,275,984	10,421,916

In CHF	"Education Grant" fund ¹	"Special purpose" fund ²	"Hubacher" fund ³	Total
2023				
Holding				
January 1, 2023	35,000	217,932	8,806,449	9,059,382
Fund creation	–	53,000	–	53,000
Fund income	–	–	623,040	623,040
Fund costs	–	–	–	–
Fund use	–35,000	–	–	–35,000
Holding				
December 31, 2023	–	270,932	9,429,490	9,700,422

¹ Fund for Janssen-Cilag AG research grant.

² Fund for non-industry-associated clinical trials, translational research and training of research specialists.

³ Fund from the bequest of Dr. Margaretha Hubacher specifically for non-Hodgkin lymphoma research.

Notes to the 2024 Annual Financial Statements

SAKK is an association based in Bern. These annual financial statements have been prepared in accordance with the requirements of Swiss law, in particular the articles on commercial accounting and financial reporting in the Swiss Code of Obligations (Art. 957 to 962).

As at December 31

Headcount

	2024	2023
Bandwidth of full-time equivalents (average for year)	> 50 to 250	> 50 to 250

As at December 31 in CHF

Disclosures on, breakdown of and commentary on items in the balance sheet and income statement

1 Accounts receivable

Accounts receivable are generally carried at their nominal amount less specific valuation allowances. A general valuation allowance is recognized for the remainder.

Outstanding accounts receivable gross	1,702,793	1,552,671
Allowance for doubtful accounts	-136,453	-118,889

Net accounts receivable **1,566,340** **1,433,782**

2 Prepaid expenses and accrued income

Prepaid expenses and accrued income consist mainly of:

Accrued income for trial SAKK 96/12	180,600	625,332
Withdrawal "Hubacher" Fund	319,697	0

As at December 31 in CHF

3 Financial assets

	24,582,684	20,801,398
Of which securities "Hubacher" fund	10,179,815	9,390,375

Financial assets are carried at their current market value. The SAKK investment rules were taken into account when investing. Fixed assets are managed externally by Swiss banks.

4 Accounts payable

Accounts payable are carried at their nominal amount.

5 Accrued liabilities and deferred income

Accrued liabilities and deferred income are made up mainly of the following items:

Contributions SAKK 96/12	456,523	447,179
Compensation, sites SAKK 96/12	232,635	168,253
Future payments	1,264,035	1,163,334
Ongoing trial accruals and deferrals	13,555,241	11,998,998

Trial accruals and deferrals comprise all active trials which, according to cost center accounting, show an amount of prefinancing or a profit. The trial accruals and deferrals were recognized as liabilities in order to cover measurement risks. The other accruals and deferrals are general accruals/deferrals to ensure that income and expenses are recognized appropriately in the period in which they arise.

January 1 to December 31 in CHF **2024** **2023**

6 Personnel expenses

Gross salaries	7,007,982	7,268,009
Third-party salaries	180,323	62,841
Social insurance	1,170,968	1,224,601
Other personnel expenses	122,484	180,695
Personnel expenses	8,481,757	8,736,146

Auditors' fee

Fee for auditing services	35,000	31,000
Fee for other services	–	–

January 1 to December 31 in CHF **2024** **2023**

Remainder of liabilities from purchase contract-type leasing transactions and other leasing liabilities not maturing or called within 12 months after the balance sheet date

Fixed rental contract archive until May 31, 2026	18,065	30,817
Fixed rental contract offices until April 30, 2026	261,765	458,089
Total non-capitalized leasing liabilities	279,831	488,907
Liabilities to pension institutions	0	1,955

January 1 to December 31 in CHF **2024** **2023**

Notes on extraordinary, non-recurring or out-of-period items in the income statement

Total out-of-period expenses	–	–
Total out-of-period income	–	–
Total out-of-period result	–	–

Cost reductions as a result of the restructuring are included here.

Net release of hidden reserves	–	–
---------------------------------------	----------	----------

Events after the balance sheet date: none

Evaluating Research Projects

For the 2024 financial statements, we have valued research projects. For this valuation, we applied the principle of itemized measurement on those long-term research projects that will incur foreseeable losses on individual trials until the year 2030 (loss-free valuation). Losses arising after this time are not taken into account based on the assumption that additional funds can be generated for those projects and that the funding requirement for trials will be significantly lower in the long run.

We based the research project valuation on the rolling multi-year plan 2025 to 2030, which has been prepared by the respective project managers. This multi-year plan takes into account the expected project funds, the external and internal study costs as well as internal hours, minus any fund withdrawals. Furthermore, we compared the approved and expected non-earmarked federal funding for the years 2025 to 2028 with the sum of staff hours and external costs planned for the loss-making projects minus project funding. The cor-

responding federal financing for CHF 5.4 million per year is subject to the annual budget decisions of the Federal Assembly.

As of the reporting date, the sum of all trial losses determined in the itemized measurement does not exceed the federal contributions for the years 2025 to 2028. A seasonalized cost presentation was taken into account.

Based on the itemized measurement and the multi-year plan, we created an accrual ensuring that the losses incurred by the long-term research projects are valued as of the reporting date. This accrual is included in the deferred income lines of the balance sheet. It covers the entire sum of all individual study losses incurred between 2025 and 2030, according to the SAKK decentralized multi-year planning as of the end of January 2025.

Miscellaneous information

The year 2024 brought an extraordinarily positive financial result, especially compared to the previous year. This is mainly thanks to receiving an exceptional legacy donation combined with the good performance of the financial markets.

Auditor's Report

**Balmer
Etienne**

Balmer-Etienne AG Bern
Schönburgstrasse 41
Postfach 561
3000 Bern 22
Telefon +41 31 336 14 14
info@roethlisbergerag.ch
balmer-etienne.ch

Statutory Auditor's Report

to the General Assembly of

Swiss Group for Clinical Cancer Research SAKK, Berne

Report of the audit of the statutory financial statements

Opinion

We have audited the financial statements of Swiss Group for Clinical Cancer Research SAKK (the company), which comprise the balance sheet as at 31 December 2024, the income statement, the statement of cash flows, the statement of changes in equity, the statement of changes in funds for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, the financial statements for the year ended 31 December 2024 comply with Swiss law and the company's articles of incorporation.

Basis for Opinion

We conducted our audit in accordance with Swiss law and Swiss Auditing Standards. Our responsibilities under those provisions and standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Statements" section of our report.

We are independent of the company in accordance with the provisions of Swiss law and the requirements of the Swiss audit profession and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other Information in the Annual Report

The Board is responsible for the other information in the annual report. The other information comprises all information included in the annual report but does not include the financial statements and our auditor's reports thereon.

Our opinion on the financial statements does not cover the other information in the annual report and we do not express any form of assurance conclusion thereon.

Statutory Auditor's Report
Page 2/3 - Balmer-Etienne AG Bern - 26 March 2025

**Balmer
Etienne**

In connection with our audit of the financial statements, our responsibility is to read the other information in the annual report and, in doing so, consider whether the other information is materially inconsistent with the financial statements, or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibility of the Board for the financial statements

The Board is responsible for the preparation of the financial statements in accordance with the provisions of Swiss law and the company's articles of incorporation, and for such internal controls as the Board determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Board is responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

Auditor's Responsibilities for the auditing of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Swiss law and Swiss Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located at the website of EXPERTSuisse: <http://www.expertsuisse.ch/en/auditreport-for-public-companies>. This description forms part of our auditor's report.

Auditor's Report

Statutory Auditor's Report
Page 3/3 - Balmer-Etienne AG Bern - 26 March 2025

**Balmer
Etienne**

Report on other legal and statutory requirements

In accordance with article 728a paragraph 1 item 3 CO and Swiss Auditing Standard 890, we confirm that an internal control system exists, which has been designed for the preparation of financial statements according to the instructions of the Board.


We further confirm that the proposed appropriation of available earnings complies with Swiss law and the company's articles of incorporation.

We recommend that the financial statements submitted to you be approved.

Berne, 26 March 2025
fco/ernstos

Balmer-Etienne AG Bern


Fabrizio Conoscenti
Audit Expert
Authorised audit expert
(Auditor in Charge)


p.p. Elsa Reinhard
M A Business and Law, University of Berne
Auditor

Financial statements 2024

Publishing Details



Publisher and point of contact

Swiss Group
for Clinical Cancer Research SAKK
SAKK Competence Center
Effingerstrasse 33
3008 Bern
Switzerland

Phone +41 31 389 91 91
Media inquiries: media@sakk.ch
sakk.ch

SAKK donations account

IBAN: CH68 0900 0000 6029 5422 0
PostFinance AG, Mingerstrasse 20, 3030 Bern
BIC/SWIFT: POFICHBEXXX
Clearing no. (BLZ): 9000

Design, text and project management

Communications,
SAKK Competence Center
etextera, Schmitten

Layout, typesetting and proofreading

Linkgroup AG, Zurich

Translations

BMP Translations AG, Basel

Printed by

Merkur Druck AG, Langenthal

About this report

The SAKK Financial Report for 2024 is available on our website at www.sakk.ch/en/annual-report

They are available in German and English.
The English version is authoritative.

Annual Portrait

The Financial Report is published as an addendum to the Annual Portrait. This reports on the events of 2024 and provides an insight into SAKK's activities.



Further information at
www.sakk.ch/en/annual-report

**Swiss Group
for Clinical Cancer Research SAKK**

Effingerstrasse 33, 3008 Bern, Switzerland
sakk.ch

